Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands

Journal of Inorganic Biochemistry

Volumn 103, Issue 5, 2009, Pages 791-796

  Marqués Gallego, Patricia ^a   Kalayda, Ganna V ^b   Jaehde, Ulrich ^b   Dulk, Hans den ^a   Brouwer, Jaap ^a   Reedijk, Jan ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Cisplatin resistance; DNA platination; Platinum accumulation; Platinum(II) compounds; Short time exposure cytotoxicity

Indexed keywords

ANTHRACENE DERIVATIVE; ANTINEOPLASTIC AGENT; CELL NUCLEUS DNA; CISPLATIN; PLATINUM [1 (9 ANTHRYL) 3 (2 PYRIDYL) 2 PROPENONE(DIMETHYL SULFOXIDE)CHLORIDE]; PLATINUM [2 [1 (9 ANTHRYL) 3 OXO 3 PROP 2 ENYLPYRIDINE]CHLORIDE]; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL MIGRATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DRUG ACCUMULATION; DRUG DNA BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CARCINOMA; TUMOR CELL LINE;

ANTHRACENES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DNA; HUMANS; PLATINUM; PLATINUM COMPOUNDS;

EID: 64449088093     PISSN: 01620134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinorgbio.2009.02.005     Document Type: Article

References (44)

1. Hannon M.J. Pure Appl. Chem. 79 (2007) 2243-2261
2. Bruijnincx P.C.A., and Sadler P.J. Curr. Opin. Chem. Biol. 12 (2008) 197-206
3. Zhang C.X., and Lippard S.J. Curr. Opin. Chem. Biol. 7 (2003) 481-489
4. Wang D., and Lippard S.J. Nat. Rev. Drug Discov. 4 (2005) 307-320
5. Moeller N., Kangarloo B.S., Puscasu I., Mock C., Krebs B., and Wolff J.E.A. Anticancer Res. 20 (2000) 4435-4439
6. Tallen G., Mock C., Gangopadhyay S.B., Kangarloo B., Krebs B., and Wolff J.E.A. Anticancer Res. 20 (2000) 445-449
7. Safaei R., and Howell S.B. Crit. Rev. Oncol./Hematol. 53 (2005) 13-23
8. Arancia G., Calcabrini A., Meschini S., and Molinari A. Cytotechnology 27 (1998) 95-111
9. Escargueil A.E., Plisov S.Y., Filhol O., Cochet C., and Larsen A.K. J. Biol. Chem. 275 (2000) 34710-34718
10. Hindenburg A.A., Gervasoni J.E., Krishna S., Stewart V.J., Rosado M., Lutzky J., Bhalla K., Baker M.A., and Taub R.N. Cancer Res. 49 (1989) 4607-4614
11. Jansen B.A.J., Wielaard P., Kalayda G.V., Ferrari M., Molenaar C., Tanke H.J., Brouwer J., and Reedijk J. J. Biol. Inorg. Chem. 9 (2004) 403-413
12. Kalayda G.V., Jansen B.A.J., Molenaar C., Wielaard P., Tanke H.J., and Reedijk J. J. Biol. Inorg. Chem. 9 (2004) 414-422
13. Kalayda G.V., Jansen B.A.J., Wielaard P., Tanke H.J., and Reedijk J. J. Biol. Inorg. Chem. 10 (2005) 305-315
14. Molenaar C., Teuben J.M., Heetebrij R.J., Tanke H.J., and Reedijk J. J. Biol. Inorg. Chem. 5 (2000) 655-665
15. Kalayda G.V., Wagner C.H., Buss I., Reedijk J., and Jaehde U. BMC Cancer 8 (2008) 1471-2407
16. Safaei R., Katano K., Larson B.J., Samimi G., Holzer A.K., Naerdemann W., Tomioka M., Goodman M., and Howell S.B. Clin. Cancer Res. 11 (2005) 756-767
17. Marqués-Gallego P., Dulk H.d., Brouwer J., Kooijman H., Spek A.L., Roubeau O., Teat S.J., and Reedijk J. Inorg. Chem. 47 (2008) 11171-11179
18. Wheate N.J., Brodie C.R., Collins J.G., Kemp S., and Aldrich-Wright J.R. Mini-Rev. Med. Chem. 7 (2007) 627-648
19. Mosmann T. J. Immunol. Methods 65 (1983) 55-63
20. Reile H., Bernhardt G., Koch M., Schonenberger H., Hollstein M., and Lux F. Cancer Chemother. Pharmacol. 30 (1992) 113-122
21. Zisowsky J., Koegel S., Leyers S., Devarakonda K., Kassack M.U., Osmak M., and Jaehde U. Biochem. Pharmacol. 73 (2007) 298-307
22. Gourdier I., Crabbe L., Andreau K., Pau B., and Kroemer G. Oncogene 23 (2004) 7449-7457
23. Mandic A., Hansson J., Linder S., and Shoshan M.C. J. Biol. Chem. 278 (2003) 9100-9106
24. Siddik Z.H. Oncogene 22 (2003) 7265-7279
25. Brabec V., and Kasparkova J. Drug Resist. Update 8 (2005) 131-146
26. Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., and Hamilton T.C. Cancer Res. 57 (1997) 850-856
27. Chao C.C.K. Mol. Pharmacol. 45 (1994) 1137-1144
28. Johnson S.W., Perez R.P., Godwin A.K., Yeung A.T., Handel L.M., Ozols R.F., and Hamilton T.C. Biochem. Pharmacol. 47 (1994) 689-697
29. Parker R.J., Eastman A., Bostickbruton F., and Reed E. J. Clin. Invest. 87 (1991) 772-777
30. Lux F., Hollstein M., Reile H., Bernhardt G., and Schonenberger H. Biol. Trace Elem. Res. 53 (1996) 113-128
31. S. Baritaki, S. Apostolakis, P. Kanellou, M.T. Dimanche-Boitrel, D.A. Spandidos, B. Bonavida, in: Reversal of Tumor Resistance to Apoptotic Stimuli by Alteration of Membrane Fluidity: Therapeutic Implications, 2007, pp. 149-190.
32. Rabik C.A., and Dolan M.E. Cancer Treat. Rev. 33 (2007) 9-23
33. Hendrich A.B., and Michalak K. Curr. Drug Targets 4 (2003) 23-30
34. Zou J., Yang X.D., An F., and Wang K. J. Inorg. Biochem. 70 (1998) 227-232
35. Platts J.A., Hibbs D.E., Hambley T.W., and Hall M.D. J. Med. Chem. 44 (2001) 472-474
36. Martelli L., Di Mario F., Botti P., Ragazzi E., Martelli M., and Kelland L. Biochem. Pharmacol. 74 (2007) 20-27
37. Kelland L.R., Sharp S.Y., O'Neill C.F., Raynaud F.I., Beale P.J., and Judson I.R. J. Inorg. Biochem. 77 (1999) 111-115
38. Kelland L. Nat. Rev. Cancer 7 (2007) 573-584
39. Perrin L.C., Prenzler P.D., Cullinane C., Phillips D.R., Denny W.A., and McFadyen W.D. J. Inorg. Biochem. 81 (2000) 111-117
40. Whittaker J., McFadyen W.D., Wickham G., Wakelin L.P.G., and Murray V. Nucleic Acids Res. 26 (1998) 3933-3939
41. Lee H.H., Palmer B.D., Baguley B.C., Chin M., McFadyen W.D., Wickham G., Thorsbournepalmer D., Wakelin L.P.G., and Denny W.A. J. Med. Chem. 35 (1992) 2983-2987
42. Palmer B.D., Lee H.H., Johnson P., Baguley B.C., Wickham G., Wakelin L.P.G., McFadyen W.D., and Denny W.A. J. Med. Chem. 33 (1990) 3008-3014
43. Perrin L.C., Cullinane C., McFadyen W.D., and Phillips D.R. Anti-Cancer Drug Des. 14 (1999) 243-252
44. Cesar E.T., de Almeida M.V., Fontes A.P.S., Pereira E.C., Garnier-Suillerot M.A., Couri M.R.C., and Felicio E.D.A. J. Inorg. Biochem. 95 (2003) 297-305